EUVIMEDEUVIMED entdecken
Systematische Übersicht

Economic Evaluation Models of Specialty Disease-Modifying Anti-rheumatic Drugs After Failure of Conventional Therapies: A Systematic Review

Ashkan F Ara, Matthew D Chenoweth

PharmacoEconomics · 07.11.2026

DOI: 10.1007/s40273-026-01683-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PharmacoEconomics, online erschienen am 07.11.2026. Verfasst von Ashkan F Ara und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, University of California, Irvine (UCI), 333 City Blvd. West, City Tower, Suite 400, Orange, CA, 928…. Die Arbeit nennt 95 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Decision-analytic models are widely used to evaluate specialty disease-modifying antirheumatic drugs in rheumatoid arthritis, but approaches to modeling uncertainty, validation, and transparency vary. We aimed to synthesize the modeling approaches of published economic evaluations of specialty disease-modifying antirheumatic drugs for adults with rheumatoid arthritis after failure or intolerance of conventional therapies. METHODS: We searched EMBASE, MEDLINE, and EconLit (up to 30 June 2026) for model-based full economic evaluations published in 2010 or later. Two reviewers screened studies and abstracted model conceptualization, scope, structure, and assumptions; model uncertainty and value-of-information analyses; model validation; and model transparency and potential conflicts of interest. RESULTS: Forty-four studies met inclusion criteria. State-transition models predominated (22 cohort Markov models and 17 microsimulations), with fewer hybrid decision tree plus Markov models (2) and discrete-event simulations (3). Most studies used payer or health-sector perspectives (31/44) and lifetime horizons (35/44). One-way sensitivity analysis (41/44) and probabilistic sensitivity analysis (40/44) were commonly reported, whereas value-of-information analysis was rare (2/44). Validation reporting largely reflected face validity; technical verification was reported in 5/44 studies and predictive validation in 1/44. No study provided a publicly available executable model, and reporting of data and input accessibility varied. CONCLUSIONS: Rheumatoid arthritis economic models commonly use state-transition frameworks and functional disability measures to project lifetime costs and health outcomes, but show persistent gaps in uncertainty analysis, validation, and reproducibility. Future models should more systematically test structural and extrapolation assumptions, strengthen validation, and improve documentation and data sharing to support policy and coverage decisions.

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Medicine, University of California, Irvine (UCI), 333 City Blvd. West, City Tower, Suite 400, Orange, CA, 92868, USA. aara@hs.uci.edu.
  • Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.

Zitieren

APA

Ara, A. F., & Chenoweth, M. D. (2026). Economic Evaluation Models of Specialty Disease-Modifying Anti-rheumatic Drugs After Failure of Conventional Therapies: A Systematic Review. PharmacoEconomics. https://doi.org/10.1007/s40273-026-01683-4

Vancouver

Ara AF, Chenoweth MD. Economic Evaluation Models of Specialty Disease-Modifying Anti-rheumatic Drugs After Failure of Conventional Therapies: A Systematic Review. PharmacoEconomics. 2026. doi:10.1007/s40273-026-01683-4

BibTeX
@article{Ara2026,
  author = {Ara, Ashkan F and Chenoweth, Matthew D},
  title = {Economic Evaluation Models of Specialty Disease-Modifying Anti-rheumatic Drugs After Failure of Conventional Therapies: A Systematic Review},
  journal = {PharmacoEconomics},
  year = {2026},
  doi = {10.1007/s40273-026-01683-4}
}
Kostenlos starten →